

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/50, 31/54, 31/505, 31/535, C07D 239/10, 239/12, 239/22, 413/04, 413/08, 413/10, 413/12, 413/14, 417/04, 417/06, 417/08, 417/10, 417/12, 417/14	A1	(11) International Publication Number: WO 96/14846 (43) International Publication Date: 23 May 1996 (23.05.96) SG 9701897-2 . RTMP copy
(21) International Application Number: PCT/US95/15025 (22) International Filing Date: 16 November 1995 (16.11.95) (30) Priority Data: 08/340,611 ✓ 16 November 1994 (16.11.94) US (60) Parent Application or Grant (63) Related by Continuation US Not furnished (CIP) Filed on Not furnished (71) Applicant (for all designated States except US): SYNAPTIC PHARMACEUTICAL CORPORATION [US/US]; 215 Col- lege Road, Paramus, NJ 07652 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): NAGARATHNAM, Dhanapalan [IN/US]; Apartment 74, 450 Island Avenue, Ramsey, NJ 07446 (US). CHIU, George [CN/US]; 13 Kelly Court, Bridgewater, NJ 08807-3057 (US). DHAR, T., G., Murali [IN/US]; 32 East Perriwinkle Lane, Hitchens Farm, Newark, DE 19711 (US). WONG, Wai, C. [US/US]; 34	(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: DIHYDROPYRIMIDINES AND USES THEREOF		
(57) Abstract This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α_{1C} receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where the antagonism of the α_{1C} receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. { DSR ② IPR }		